Capital World Investors
GENB

Capital World Investors’s Generate Biomedicines GENB Stock Holding History

Capital World Investors’s Portfolio GENB Stock Details GENB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$71.1M Buy
4,215,632
+211,483
+5% +$2.88M 0.01% 448
2026
Q1 		$50.1M Buy
+4,004,149
New +$48.9M 0.01% 457

Other funds holding GENB

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital World Investors's GENB Position: Q2 2026 in Review

Capital World Investors increased its Generate Biomedicines (GENB) stake by 5.3% in Q2 2026, buying an estimated $2.88M and bringing the position to 4,215,632 shares worth $71.1M. The position accounts for 0.01% of the portfolio, ranked #448.

Capital World Investors first reported a position in GENB in Q1 2026 and has held it in 2 quarters since. 86 funds tracked by Wall St. Rank hold GENB as of Q2 2026.

  • Capital World Investors held 4,215,632 shares of Generate Biomedicines worth $71.1M as of Q2 2026.
  • Capital World Investors bought 211,483 Generate Biomedicines shares in Q2 2026, an estimated $2.88M.
  • Generate Biomedicines made up 0.01% of Capital World Investors's portfolio in Q2 2026, its #448 holding.
  • Capital World Investors first reported a position in Generate Biomedicines in Q1 2026 and has held it in 2 quarters since.
  • 86 funds tracked by Wall St. Rank held Generate Biomedicines as of Q2 2026.

Based on Capital World Investors's 13F filing for Q2 2026, filed 12 Aug 2026.